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a  b  s  t  r  a  c  t
Perﬂuorooctanoic  acid  (PFOA)  is a man-made  surfactant  with  a  number  of industrial  applications.  It
has a long  half-life  environmentally  and biologically.  Past  studies  suggest  a direct  relationship  between
plasma  cholesterol  and PFOA  serum  concentrations  in humans  and an  inverse  one  in rodents  fed  standard
rodent  chow,  making  it difﬁcult  to  examine  mechanisms  responsible  for the  potential  PFOA-induced
hypercholesterolemia  and  altered  sterol  metabolism.  To  examine  dietary  modiﬁcation  of  PFOA-induced
effects,  C57BL/6  and  BALB/c  mice  were  fed  PFOA  in  a fat-  and  cholesterol-containing  diet. When  fed  these
high fat  diets,  PFOA  ingestion  resulted  in  marked  hypercholesterolemia  in  male  and  female  C57BL/6  mice
and  less  robust  hypercholesterolemia  in  male  BALB/c  mice.  The  PFOA-induced  hypercholesterolemia
appeared to be the  result  of  increased  liver  masses  and  altered  expression  of  genes  associated  with
hepatic  sterol  output,  speciﬁcally  bile  acid production.  mRNA  levels  of genes  associated  with  sterol  input
were reduced  only  in  C57BL/6  females,  the mice  with  the  greatest  increase  in plasma  cholesterol  levels.holesterol
ietary fat
Strain-speciﬁc  PFOA-induced  changes  in  cholesterol  concentrations  in mammary  tissues  and  ovaries
paralleled  changes  in  plasma  cholesterol  levels.  mRNA  levels  of  sterol-related  genes  were  reduced  in
ovaries  of  C57BL/6  but  not  in  BALB/c  mice  and not  in  mammary  tissues.  Our  data  suggest  that  PFOA
ingestion  leads  to hypercholesterolemia  in  mice  fed  fat and  cholesterol  and  effects  are  dependent  upon
the genetic  background  and  gender  of the mice  with  C57BL/6  female  mice  being  most  responsive  to  PFOA.
rs.  Pu© 2015  The  Autho
. Introduction
Perﬂuorooctanoic acid (PFOA) is a saturated eight carbon chain
rganic acid, perﬂuoroalkyl substance (PFAS) with all hydrogen
eplaced by ﬂuorine. PFOA is primarily used to produce other PFASs
or stain- and stick-resistant coatings (Teﬂon), water-resistant
oatings (Gor-Tex), and food contact paper [29,4,42]. Because of
heir widespread use over the past several decades and rela-
ively long half-lives [45] some of these PFASs, including PFOA,
re prevalent throughout the world from populated, industrialized
ocations to remote locations [3,11]. Consequently, PFOA expo-
ure is widespread throughout the US general population [7,39].
hough essentially everyone has measurable levels of PFOA due
o their detection in almost every ecosystem worldwide, serum
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levels are somewhat greater in areas near facilities that use PFOA
[13,51] and considerably higher in perﬂuoroalkyl production work-
ers [9,43,44,46,47,56,57,66]. Though PFOA production in the US has
decreased markedly in the past several years, along with serum
concentrations in people in the US (NHANES), and should cease in
2015 (EPA Stewardship Plan), PFOA remains a human health con-
cern due to continuing production and use worldwide, relatively
long half-lives in humans [45], persistence in the environment, and
degradation of other PFAAs into PFOA [4].
Controversy exists over whether PFOA is hypo- or hyper-
cholesteremic. Human gene expression data from different
studies suggest a hypercholesteremic hypothesis. PFOA upreg-
ulated cholesterol biosynthesis genes in human hepatocytes
[5,50]. In a study of population co-exposed to PFOA and
perﬂuorooctanoate sulfonate, expression of genes involved in
reverse cholesterol transport expression, a cause of hyper-
cholesterolemia, were reduced with PFOA exposure [17]. In
addition, PFOA exposure has been signiﬁcantly associated
with an increased risk of clinical hypercholesterolemia [60,18]
and increased plasma cholesterol concentrations in national
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opulation studies [39,14,20,75], in communities near perﬂuo-
oalkyl production facilities [60,18,16,19] and in perﬂuoroalkyl
orkers [9,26,56,57]. While most studies have been cross-
ectional, signiﬁcant associations between PFOA and cholesterol
ave been found in exposed communities [16,71] and occupa-
ional cohorts as well [9,56,57] though increases attributable to
FOA are small compared to other hypercholesteremic factors
44]. In many studies, effect estimates, and resultant cholesterol
ncreases, are strongest at serum PFOA concentrations below 10
g/mL (corresponding to 95% of US population exposure) although
hey remain signiﬁcant for all concentrations, with the inﬂection
oint ≈25–40 ng/mL [60,18]. Regardless, though direction, mag-
itude and signiﬁcance of the PFOA-cholesterol association vary
cross studies, especially for HDL and LDL, human experimental and
pidemiological data suggest PFOA is indeed hypercholesterolemic.
A change in plasma cholesterol levels is often an indication of
 change in hepatic sterol balance [59] and can lead to altered
terol metabolism in a variety of extra-hepatic tissues, including
teroidogenic tissues. Hepatic sterol balance plays a key role in
aintaining sterol balance in the whole body [59]. A positive sterol
alance would occur with increased dietary cholesterol and will
ften lead to a reduction in LDL receptor (LDLR) expression lev-
ls which will in turn lead to fewer LDL particles being taken up
y the liver and an increase in plasma LDL-cholesterol levels [12].
s most LDL is taken up by the liver [72], a reduction in uptake
ould lead to an increase in plasma levels. A change in sterol bal-
nce can also occur if sterol synthesis or bile acid production rates
re altered. As the peripheral tissues take up a majority of LDL-
holesterol via receptor-independent processes or via receptors
hat are independent of tissue sterol balance, an increase in circulat-
ng lipoprotein-cholesterol would lead to an increase in uptake by
eripheral tissues. An increase in tissue cholesterol could directly
ffect tissues, such as ovaries that synthesize estradiol and indi-
ectly affect tissues that rely on the steroid products produced by
he other tissues, including mammary tissues that rely on estradiol.
In studies with rodents, PFOA-treated animals often become
ypocholesterolemic, opposite of that which occurs in humans
2,22,28,35–37,52,73]. In most of these previous studies, rodents
onsumed a standard chow diet containing 4% fat and very little
holesterol. It has been proposed that the effect occurs because
FOA will activate peroxisome proliferator-activated receptor 
PPAR)  more readily in rodents than in humans, and PPARs can be
ypolipidemic [24,2,38,54,68]. However, other studies suggest that
ome PFOA metabolic effects are PPAR-independent [55,27,54].
ow animals respond to PFOA when sterol balance is altered with
ietary factors and cholesterol, as occurs in humans, is unknown,
hough it appears that dietary fat can modify the effect of PFOA on
ther parameters [61].
Thus, the purpose of the current study was to determine the
mpact of dietary PFOA when fed in combination with a diet con-
aining fat and cholesterol, more similar to that consumed by
umans, using strains of mice that respond differently to PFOA
ith respect to sexual maturity [74] and to dietary factors [30,48],
nd have been shown previously to become hypocholeserolemic
hen exposed to PFOA [52,73]. The use of mice that become hyper-
holesteremic in response to PFOA and a high-fat diet would be
ery useful in assessing human PFOA response and addressing the
ontradictions between human and rodent data.
. Materials and methods.1. Animals and diets
Male and female C57BL/6 and BALB/c mice were purchased from
he Jackson Laboratories (Bar Harbor, ME)  at weaning, randomlyReports 3 (2016) 46–54 47
separated into 8 groups, and fed pelleted chow upon arrival (Harlan,
Madison, WI); 8 groups consisted of 2 different sexes, two differ-
ent strains of mice, and two  different PFOA treatments. Mice were
housed 3 per cage in a temperature and humidity controlled room
and subjected to 12 h of light and 12 h of darkness. Four to ﬁve days
after arrival, mice were weighed and distributed between cages
to ensure similar initial body weights per treatment, and began
consuming one of two  diets (Research Diets, Inc.); we chose to
study younger mice just prior to sexual maturity as PFOA has been
described as an endocrine disruptor and could impact metabolism
in endocrine tissues as they mature [1,74]. Both diets contained
0.25% cholesterol and 32% fat (kcal) with soybean oil as the primary
oil. One diet was the control diet and contained no added PFOA.
The other diet contained 3.5 mg  PFOA (Sigma–Aldrich)/kg diet. We
chose this amount of PFOA to add because we wanted mice to con-
sume 0.5 mg  PFOA/kg body weight and adult mice consume ≈3.5 g
high fat diet [33]. Thus, a 22 g mouse would consume ≈12.3 g
PFOA per whole body per day or ≈0.56 mg  PFOA per kg body weight
per day. PFOA was added to the diet and not gavaged daily so that
mice would be exposed to PFOA throughout the day and mimic
human exposure to PFOA. Weekly individual body weights and
food consumption of each cage were obtained to ensure adequate
growth and to determine the dose of PFOA consumed each day per
kg body weight, respectively; each group consisted of 2 cages of 3
mice each (6 male and 6 female mice of each strain per treatment).
Animal protocols were approved by the University of Cincinnati
Institutional Animal Care and Use Committee.
After 5 weeks, body fat mass was measured by MRI  (Echo).
The following week the mice were fasted 6 h, anesthetized, exsan-
guinated and tissues collected rapidly and stored as needed. Diethyl
ether was  used as an anesthesia (prior to the AVMA report in 2013)
to ensure accurate PFOA measurements in plasma not confounded
by interfering anesthetics. Additional care was taken so blood and
plasma were collected and stored using syringes and tubes made
of polypropylene. Plasma from each animal per group was pooled,
stored frozen, and shipped to the Centers for Disease Control and
Prevention (CDC) where it was analyzed for PFOA using online solid
phase extraction coupled with reversed-phase high-performance
liquid chromatography isotope-dilution tandem mass spectrome-
try as described [27]; samples were pooled in this initial study to
ensure adequate volumes for all plasma measurements proposed.
To ensure that the measured PFOA concentrations fell within the
calibration range, necessary dilution of the plasma was performed.
Blanks and quality control materials were analyzed along with the
study samples to ensure the accuracy and reliability of the data [27].
2.2. Tissue and plasma steroid levels
Plasma cholesterol levels in each sample were measured enzy-
matically in duplicate (Thermo Electron). Plasma from each animal
per group was pooled and separated into lipoproteins by fast-
protein liquid chromatography (FPLC) using two  Sephadex columns
in tandem [31]. Pieces of liver (males and females) and mammary
tissue and one ovary (females) were collected after exsanguina-
tion, saponﬁed in alcoholic KOH, sterol extracted, and mass of sterol
measured by gas liquid chromatography using stigmastanol as an
internal standard. Estradiol levels were measured in duplicate in
plasma of some of the females (2–5 mice per group) by EIA (Cayman
Chemical).
2.3. Real time PCRLivers, ovaries, and pieces of mammary tissues were collected
rapidly after exsanguination, snap frozen in liquid nitrogen, and
stored at −80 ◦C until use. Tissue RNA was  isolated using TRIzol®
and stored in FORMAzol® at −80 ◦C. RNA was treated with RNase-
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Table  1
Static measurements in male and female mice fed high fat diets and cholesterol plus
no  added PFOA (control) or added PFOA.
C57BL/6 BALB/c
Control PFOA Control PFOA
Male
Body weight (g) 26.3 ± 0.4 25.6 ± 0.2 24.8 ± 1.0 24.8 ± 0.4
Body fat (%) 9.4 ± 1.1 8.4 ± 1.1 10.6 ± 0.8 11.0 ± 1.1
Liver (% body) 5.2 ± 0.1 8.7 ± 0.3* 5.5 ± 0.3 8.5 ± 0.4*
PFOA levels (ng/ml) 2 26,900 5 28,200
Female
Body weight (g) 20.4 ± 0.6 20.3 ± 0.5 20.7 ± 0.2 21.0 ± 0.4
Body fat (%) 10.5 ± 0.8 10.6 ± 0.9 10.1 ± 0.6 10.1 ± 0.5
Liver (% body) 5.6 ± 0.3 9.3 ± 0.7* 5.7 ± 0.2 9.4 ± 0.3*
PFOA levels (ng/ml)a 28 44,300 86 35,600
Estradiol (ng/ml)b 11.7 ± 1.8 8.6 ± 2.0 7.5 ± 1.5 10.8 ± 1.7
Note: Data are presented as means ± SEM (n = 6).








































Fig. 1. Plasma cholesterol concentrations in C57BL/6 (A) and BALB/c (B) male and
female mice. Mice were weaned and fed diets containing fat plus cholesterol. Half
of  the mice received no dietary PFOA and half received 3.5 mg/kg diet so that
mice would consume ≈1 mg/kg body weight. After 6 weeks of dietary treatment,
mice were anesthetized, exsanguinated and plasma collected. Data represent aver-
ages ± SEM (n = 5–6). Differences from mice fed control diets are depicted by *a Plasma of mice within each group are pooled for PFOA levels only.
b n = 5, 2, 4, and 4 for control C57, PFOA C57, control BALB/c, and PFOA BALB/c,
espectively.
ree DNase I and reverse transcribed to cDNA by SuperScript II
everse transcriptase using random hexamers. PCR assays were
erformed on a Bio-Rad iCycler iQ real-time PCR Detection Sys-
em using SYBR green as our ﬂuorophore; primers will be given
pon request. A serial dilution of a randomly-picked sample was
sed to generate a standard curve for each gene examined, using
t values and log of dilutions as axes. Relative mRNA levels in
ach sample were obtained from dilution curves for each gene,
nd numbers converted back from log transformations. The rel-
tive levels of mRNA for the genes of interest were determined
y generating a ratio of the gene of interest vs cyclophilin as the
eference/housekeeping gene.
.4. Statistics
Sex-speciﬁc means ± SEM of body weight, body fat%, liver (%
ody weight) and plasma and liver cholesterol concentrations were
alculated for PFOA exposed and non-exposed within each strain.
train speciﬁc mammary and ovary cholesterol concentrations
ere calculated for the female animals. For the sake of presenta-
ion, signiﬁcant differences between each dietary group (±PFOA)
f each strain and sex were determined by two-tailed student’s t-
ests (P < 0.05). Signiﬁcant differences between each dietary group
±PFOA) of each strain and sex were determined by two-tailed
tudent’s t-tests for mRNA analyses (P < 0.05).
Linear regression analyses were performed with PFOA exposure
s a binary variable (±PFOA) to test for the effect of the PFOA expo-
ure on various outcomes with simultaneous adjustment for sex
nd strain. When comparing plasma and tissue cholesterol concen-
rations between mice of different groups, plasma cholesterol was
sed as a covariate for tissue cholesterol concentrations, because
ptake of cholesterol can be directly related to plasma cholesterol in
xtrahepatic tissues, and liver weight, as liver is a source of plasma
holesterol, was used as a covariate for plasma cholesterol levels
59].
. Results
These studies are unique compared to other studies in rodents
n that mice were fed diets with fat and cholesterol to simulate
uman dietary composition and results. Dietary PFOA did not affect
ody weight after treatment in males or females of either strain
Table 1, Supplemental Fig. 1). Percent body fat was  also similar
n each group of animals (Table 1). Not surprisingly, liver weight
expressed as a percent of body weight) was increased ≈60% in mice(P  < 0.05).
fed PFOA compared to control mice (Table 1). When liver weight
was subtracted from body weight, the only group that had signif-
icantly lower body weights with dietary PFOA was C57BL/6 males
(P = 0.003; 25.0 ± 0.3 vs 23.6 ± 0.2 g); body weights minus liver
weights were not different for female C57BL/6 mice (19.3 ± 0.4 vs
18.5 ± 0.5) or male or females BALB/c mice respectively (23.5 ± 0.8
vs 22.8 ± 0.4 and 19.5 ± 0.2 vs 19.0 ± 0.3 g). It was not surprising
that body weights were slightly less in PFOA-fed mice as mice con-
suming diets laced with PFOA appeared to eat slightly less food
(Supplemental Table 1). Plasma estradiol levels were not signiﬁ-
cantly affected by dietary PFOA in this study of sexually mature
mice fed fat and cholesterol (Table 1).
The amount of food consumed by each cage of PFOA-fed
mice was measured each week with an average of 2.6 ± 0.1 and
2.5 ± 0.1 g/day for each female and male mouse, respectively. As
the size of the mice differed from week 1 to week 6 of the study,
mice consumed ≈0.55 mg  PFOA per day per kg body weight at
4 weeks of age in both males and females as they have similar
body masses. At 10 weeks of age, male mice consumed ≈0.33 and
female mice consumed ≈0.44 mg  PFOA per day per kg body weight
due to the gender differences in body weights of the older mice.
This amount of PFOA resulted in average plasma levels of circu-
lating PFOA in mice of ≈27,600 ng PFOA/ml plasma in males and
≈39,000 ng PFOA/ml plasma in females. Even though the plasma
PFOA concentrations in our study are many fold greater than the
means of a number of human cohorts, they are within the range of
human occupational exposures, though at the higher end [9,44,57].
Unlike the lack of effect of PFOA on body fat, PFOA resulted in a
70% increase in plasma cholesterol levels in female C57BL/6 mice
and a more modest increase of 35% in male C57BL/6 mice (Fig. 1);
dietary fat and cholesterol resulted in plasma cholesterol levels in
control mice of ≈150 mg/dl in C57BL/6 mice and ≈100 mg/dl in
BALB/c mice. In BALB/c mice, plasma cholesterol levels increased
somewhat (≈20%) in male mice fed PFOA whereas PFOA had no
effect on plasma cholesterol levels in female mice. In regression
analyses, the effect of PFOA on plasma cholesterol levels was  sig-
niﬁcant in both C57BL/6 and BALB/c mice in models without liver
weight, but not signiﬁcant with liver weight in the model. These
PFOA-induced increases in plasma cholesterol levels in C57BL/6
animals were associated with a “large HDL” as determined by FPLC
(Fig. 2); additional studies would need to determine what type of
particle these are, i.e. do they contain apoB, apoE, or apoAI.
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Table  2
Linear regression analyses for liver weight%, and plasma, liver, mammary and ovarian cholesterol concentrations.
Dependent variable PFOA Sex Liver weight %
C57BL/6 Beta SE P value Beta SE P value Beta SE P value
Liver weight% 3.594 0.479 <0.0001 0.438 0.479 0.371
Liver cholesterol −1.195 1.182 0.324 12.275 1.183 <0.0001
Plasma cholesterol 52.319 11.992 0.0003 −1.829 11.992 0.88
Plasma cholesterol 13.921 20.687 0.509 −6.692 11.214 0.558 10.730 4.897 0.041
BALB/c Beta SE P value Beta SE P value Beta SE P value
Liver weight% 3.350 0.365 <0.0001 0.567 0.365 0.136
Liver cholesterol −22.343 2.793 <0.0001 30.781 2.793 <0.0001
Plasma cholesterol 14.700 6.068 0.025 −4.850 6.068 0.433
Plasma cholesterol 12.456 13.899 0.381 −5.230 6.669 0.435 0.670 3.711 0.859
PFOA  Strain (BALB/c) Plasma cholesterol
Both strains Beta SE P value Beta SE P value Beta SE P value
Ovarya 0.789 1.185 0.514 −2.625 1.185 0.039
Ovary 0.947 1.354 0.493 −2.895 1.584 0.084 −0.005 0.020 0.794
Mammarya 0.180 0.129 0.177 0.080 0.129 0.541










































gstimates (p values) for PFOA and cofactors. Bold represents signiﬁcant differences.
a Line one for each tissue represents analyses without using plasma cholesterol a
Tissue cholesterol concentrations were determined next. Hep-
tic cholesterol concentrations in male and female C57BL/6 mice
ed fat and cholesterol were ≈5 and ≈20 mg/g, respectively (Fig. 3A),
igher than liver cholesterol concentrations in chow-fed mice of
2 mg/g [49]. Dietary fat and cholesterol resulted in even greater
levated liver cholesterol concentrations in BALB/c mice (Fig. 3B).
hereas dietary PFOA had no impact on hepatic cholesterol levels
n C57BL/6 mice, hepatic cholesterol concentrations were reduced
igniﬁcantly in male and female BALB/c mice fed PFOA (Fig. 3B and
able 2). In mammary tissues, there was a modest increase (≈25%)
n cholesterol concentrations in C57BL/6 mice fed PFOA, whereas
here was no statistical effect of PFOA in cholesterol concentra-
ions in mammary tissues of BALB/c mice (Fig. 4A). In regression
nalyses, mammary cholesterol was increased only when plasma
holesterol was included as the covariate. In ovaries, cholesterol
oncentration in C57BL/6 mice tended to be increased (P=0.069)
ith PFOA whereas there was no little change in ovarian choles-
erol in BALB/c mice (Fig. 4B). In regression analyses of both strains
ombined, there was no effect of ovarian cholesterol when plasma
holesterol was included as a covariate but the strain effect was
igniﬁcant or marginally signiﬁcant (Table 2). The limited number
f animals in each group prevented us from doing strain-speciﬁc
egression analyses of the mammary and ovary cholesterol out-
omes, which were measured only in females. Model ﬁt was  much
etter for the models examining the effects of PFOA on liver weight
nd liver cholesterol with R-Square >0.80 for all models (explain-
ng more than 80% of the total variance) except for liver weight% in
57BL/6 where the R-Square was a very respectable 0.73. Model ﬁt
or plasma cholesterol was not as good (C57BL/6, R-Square = 0.59
nd BALB/c R-Square = 0.49) and <0.24 all for models examining
ammary and ovary cholesterol concentration as outcomes.
In addition to concentrations of sterol in tissues, mRNA levels
f genes involved in sterol input (LDLR and HMGR) and output
cyp7a1), transport of sterol into the mitochondria (StAR), and
ptake of estradiol (ER) were measured in livers, ovaries, and/or
ammary tissues. PFOA did not affect the relative levels of mRNA of
DLR and HMGR in the liver in male C57BL/6 mice or male or female
ALB/c mice (Fig. 5 A&B&D). However, mRNA levels were reduced
n the C57BL/6 female mice fed PFOA (P < 0.05) (Fig. 5C). As with
DLR and HMGR, dietary PFOA led to a decrease of StAR mRNA only
n the C57BL/6 female (Fig. 5). SR-BI was not affected by PFOA in any
roup of mice (Fig. 5). The biggest change in liver mRNA levels was  avariate whereas line two uses plasma cholesterol.
reduction in cyp7a1 mRNA as all mice fed PFOA had reduced levels
of cyp7a1 mRNA. The effect could be direct because mRNA levels of
FXR, a major regulator of cyp7a1, were not affected by PFOA in male
and female C57BL/6 (0.97 ± 0.07 vs 0.95 ± 0.05 and 1.15 ± 0.08 vs
0.99 ± 0.08, respectively) or BALB/c mice (0.77 ± 0.06 vs 0.73 ± 0.08
and 1.19 ± 0.07 vs 1.11 ± 0.07, respectively). In ovaries, LDLR and
HMGR mRNA levels were reduced or tended to be reduced in
C57BL/6 females, respectively, and were unaffected in BALB/c mice
(Fig. 6A&B). StAR was also reduced signiﬁcantly in ovaries of the
C57BL/6 females but remained unaffected in the BALB/c mice. PFOA
did not affect gene expression in mammary tissue (Fig. 6C&D).
Finally, PPAR activation was  examined as a possible cause of
metabolic changes by measuring the mRNA levels of PPAR and of
a downstream target of PPAR (CPT-1). There was  little effect of
PFOA on PPAR or CPT-1 mRNA levels in livers of C57BL/6 mice or
female BALB/c mice (Fig. 7A,C,&D). However, there was a trend for
an increase in PPAR (P = 0.08) and a signiﬁcant increase in CPT-1
levels in male BALB/c mice fed PFOA-laced diets (Fig. 7B).
4. Discussion
The major ﬁndings of these studies were two-fold. First and
possibly most important, mice exposed to PFOA became hyper-
cholesterolemic (deﬁned as a signiﬁcant increase in plasma
cholesterol levels compared to control mice) when consuming diets
containing cholesterol and fat. The effect was  modiﬁed by genet-
ics (C57BL/6 vs BALB/c) as well as gender (male vs female). Both
C57BL/6 male and female mice became hypercholesterolemic when
PFOA was  fed in combination with cholesterol and fat. In contrast,
only male BALB/c mice became hypercholesterolemic when fed
PFOA-laced diets in combination with cholesterol and fat. A strain
difference was not unexpected as previous studies have shown
that C57BL/6 and BALB/c mice respond differently to dietary fac-
tors with respect to lipid metabolism [30] and mammary tissue
metabolism [48,74]. Importantly, though diets resulted in marked
increases in PFOA levels, there was not a reduction in body weight,
as can happen with exposure to increased levels of PFOA.
The difference in the response to PFOA with respect to plasma
cholesterol levels in these studies versus past studies was likely
because PFOA was fed in combination with components of a
typical Westernized diet, with increased levels of fat (≈33% calo-
ries) and cholesterol (≈300 mg/day), more like diets consumed
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Fig. 2. Lipoprotein-cholesterol in C57BL/6 and BALB/c male and female mice. Plasma
collected in animals described in Fig. 1 was pooled by group and lipoproteins sepa-
rated by FPLC. Cholesterol content in each fraction was measured enzymatically.
Fig. 3. Cholesterol concentration in the livers of C57BL/6 (A) and BALB/c (B) male
and female mice. Livers were collected from mice described in Fig. 1 and choles-
terol  measured by gas chromatography. Data represent averages ± SEM (n = 5–6).
Differences from mice fed control diets are depicted by * (P < 0.05).
Fig. 4. Cholesterol concentration in the mammary tissues and ovaries of C57BL/6
(A)  and BALB/c (B) female mice. Tissues were collected from mice described in Fig. 1
and cholesterol measured by gas chromatography. Data represent averages ± SEM
(n = 5–6). Differences from mice fed control diets are depicted by * (P < 0.05) and by
#  (P = 0.069).
Fig. 5. Relative mRNA levels of genes involved in sterol metabolism of livers of
C57BL/6 (A, C) and BALB/c (B, D) male and female mice. Livers were collected
from mice described in Fig. 1 and mRNA levels measured by real time PCR using
cyclophilin as our housekeeping gene. Data represent averages ± SEM (n = 5–6). Dif-
ferences from mice fed control diets are depicted by * (P < 0.05).
by humans in resource-rich countries [8,40], compared to typi-
cal rodent chow. By adding cholesterol to the diet, whole body
sterol balance was  changed to mimic  that found in humans con-
suming similar diets. This is important as adaptive changes in an
individual’s plasma cholesterol level appear to depend, at least
partly, on their hepatic sterol synthesis rates, LDLR levels, and bile
acid synthesis rates [59,63]. When exogenous cholesterol enters
hepatocytes, intracellular cholesterol concentrations increase. Reg-
ulation of intracellular cholesterol occurs through a balance of input
versus output of cholesterol. To account for the exogenous choles-
terol, input from other sources, including de novo synthesis and
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Fig. 6. Relative mRNA levels of genes involved in sterol metabolism of mammary
tissues and ovaries of C57BL/6 (A, C) and BALB/c (B, D) female mice. Tissues were
collected from mice described in Fig. 1 and mRNA levels measured by real time






























Fig. 7. Relative mRNA levels of genes involved PPAR signaling in livers of C57BL/6
(A, C) and BALB/c (B, D) male and female mice. Livers were collected from mice
described in Fig. 1 and mRNA levels measured by real time PCR using cyclophilin asn  = 5–6). Differences from mice fed control diets are depicted by * (P < 0.05) and by
 (P = 0.056).
ipoprotein uptake, is reduced and output of cholesterol, including
ile acid synthesis, is increased. On a mechanistic level, the levels
f HMGR and LDLR are regulated by SREBP-2 such that decreases
n the mature form of SREBP result in reductions in HMGR and
DLR levels [23]. Because most LDL is cleared by the liver [72],
 reduction in hepatic LDLR levels will lead to more cholesterol
eing retained in the plasma [12]. Likewise, cholesterol is retained
n the body when bile acid synthesis rates are decreased [12,62]. In
he current study, the control groups (without PFOA) already have
levated plasma and/or liver cholesterol levels compared to previ-
us studies in which mice were fed standard rodent chow [49,65];
tandard rodent chows have on average 4% fat (wt/wt) and 0.002%
holesterol (wt/wt).
In our mice, the increase in plasma cholesterol occurred in the
DL fraction. In humans, signiﬁcant increases in LDL with increas-
ng PFOA have been seen in national adolescent studies [20,75],
xposed communities [60,16,18,19] and occupational cohorts [56].
uman HDL cholesterol and PFOA studies are less consistent,
hough all show a decrease in HDL as PFOA increases [20,21,47,66].
s such, PFOA-induced hypercholesteremia in humans appears to
e the result of elevated LDL and reduced HDL cholesterol. The dif-
erence in where the excess cholesterol is carried in the plasma in
umans and mice is likely due to one of two metabolic differences
etween species. It is possible that HDL-cholesterol increases in
umans but the cholesterol is transferred to VLDL, via cholesteryl
ster transport protein (CETP), and subsequently converted to LDL,
hereas mice cannot transfer cholesterol between lipoproteins as
hey lack this enzyme. Alternatively, excess cholesterol is secretedour housekeeping gene. Data represent averages ± SEM (n = 5–6). Differences from
mice fed control diets are depicted by * (P < 0.05) and # (P = 0.08).
as VLDL in humans and as HDL in mice. Additional studies would
need to be completed in mice to determine if HDL  production was
increased followed by a transfer of HDL-cholesterol to VLDL using
CETP transgenic mice.
We also examined possible causes of the hypercholesterolemia.
Initially we  examined expression of genes involved in sterol bal-
ance in the liver. Importantly, PFOA treatment led to a reduction
in the mRNA levels cyp7a1 in every group treated; PFOA-induced
cyp7a1 downregulation was  previously observed in rats fed a nor-
mal  chow diet [36] and human hepatocytes [53]. All groups with
≥50% reduction in cyp7a1 mRNA levels (C57BL/6 male and female
and BALB/c male mice) had increased plasma cholesterol levels.
The increase was greatest in C57BL/6 females, possibly due to the
suppression of LDLR in those mice as well. A reduction in LDLR
mRNA levels that are accompanied by reductions of HMGR mRNA
levels, as detected in the C57BL/6 females, suggests an increase in
the subcellular pool of cholesterol regulating transcription of both
genes [10]. The decrease in liver cholesterol levels in BALB/c mice
initially seemed inconsistent in mice with reduced bile acid pro-
duction. However, results could be confounded by the fact that
PFOA can activate PPAR and BALB/c mice have more PPAR than
C57BL/6 mice [76]; increased mRNA levels of PPAR and CPT-1 is
an indication of activated PPAR and was  found in BALB/c male
mice. As PPAR is hypolipidemic and can lead to a reduction in
liver cholesterol levels [64], the hypolipidemic effect of PFOA in
BALB/c might override any other metabolic effect. At present, no
human in vivo studies have examined reduced bile acid production.
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xpression associated with cholesterol mobilization and reverse
holesterol transport [17] and upregulated circulating microRNAs
hat impair reverse cholesterol transport [66], both consistent with
educed bile acid production and cholesterol excretion. Though the
urrent studies focused on the liver, the intestine can also play a role
n sterol balance if cholesterol absorption were changed by PFOA as
ell as other extrahepatic tissues and should be the focus of future
tudies.
The effect on plasma cholesterol levels was not due solely to
hanges in genes involved in sterol balance. In linear regression
nalyses, we also found that the larger liver size, containing a sig-
iﬁcant pool of cholesterol, also played a role in the PFOA-induced
ypercholesterolemia. Based on previous studies, the increased
iver size is most likely the result of hypertrophy [61]. The effect was
lso not mediated by an increase in food consumption (Supplemen-
al Table I), and in fact mice may  have consumed less food when
.5 mg  PFOA was added to each kg of diet. Thus, a change in sterol
alance as the result of regulation of genes involved with sterol
alance combined with larger livers appeared to be responsible for
he hypercholesterolemia in the C57BL/6 mice.
Our second major ﬁnding was that dietary PFOA affected sterol
etabolism in ovaries and mammary tissues. In the current study,
holesterol concentrations were increased in mammary tissues and
rended to be increased in ovaries in the C57BL/6 females but not
ALB/c females. When plasma cholesterol was also included as
 covariate, mammary cholesterol was signiﬁcantly increased by
FOA exposure suggesting that the effect on the mammary was  the
esult of a change in plasma cholesterol levels. The  standard error
stimates for these outcomes were quite large relative to the effect
stimates, probably reﬂecting some scatter in the small number of
ice studied. No effects were found for ovarian cholesterol, most
ikely as the differences were not <0.05. Clearly larger sample sizes
re needed to better contrast the relationships between PFOA and
ammary and ovarian cholesterol concentrations and metabolism
n these two mouse strains when sterol balance is altered.
Even if tissue cholesterol concentrations are not affected, it is
ossible to detect differences in metabolism if the putative reg-
latory pool of cholesterol is changed [10]. For example, though
varian total cholesterol was not statistically different in groups
ith or without dietary PFOA, sterol balance across this tissue of
57BL/6 females was likely affected as there were reductions in
he genes regulated by sterol balance in these tissues (LDLR and
MGR), suggesting altered sterol balance. The C57BL/6 females
lso had reduced StAR mRNA levels which could be the reason for
he lack of increase in estradiol levels in the tissues with greater
terol levels; StAR mRNA levels have been shown to be reduced
y other perﬂuronated compounds [58,32]. Though a decrease in
tAR mRNA levels might suggest a reduction in transport of pre-
ursor for steroidogenesis, substrate supply could be greater in the
varies of PFOA-treated mice, leading to relatively similar estradiol
evels between both strains of mice. There was no change in mRNA
evels of any of the proteins measured in the mammary tissues of
ice fed PFOA, possibly because there was only a 20% increase in
issue cholesterol levels.
The lack of effect of PFOA on mRNA levels in tissues of BALB/c
emale mice could help delineate the process by which PFOA is
ffecting peripheral tissues. As tissue cholesterol levels and mRNA
evels of sterol-related proteins did not change in BALB/c female
ice fed PFOA, one might assume that the effects of PFOA on
terol metabolism in mammary tissues and ovaries are medi-
ted by uptake of plasma cholesterol and not a direct effect of
FOA; BALB/c mice were normocholesterolemic with dietary PFOA
hereas C57BL/6 female mice were hypercholesterolemic. There
as been much speculation of the impact of PFOA on peripheral
issue metabolism, especially in females, due to its potential func-Reports 3 (2016) 46–54
tion as an endocrine disruptor [68]. As cholesterol is needed for
tissue proliferation, i.e. mammary tissue development, a change in
sterol content or metabolism could affect mammary tissue devel-
opment. Indeed, PFOA does affect mammary tissue development
in a strain dependent manner [74,76]. In mice that become hypoc-
holesterolemic with PFOA, i.e. previous studies in which mice were
fed chow, PFOA can delay mammary tissue development in BALB/c
mice at all doses of PFOA (0.1–10 mg/kg BW)  and in C57BL/6 mice
at the high dose only [74]. It will be interesting to know how PFOA
affects mammary tissue development in mice that become hyperc-
holesterolemic with consumption of PFOA. In fact, the combination
of diet and PFOA could be quite important as it relates to the human
population in that a high fat diet alone can affect mammary tis-
sue development [48]. Though a full study on breast maturation
and PFOA has not been completed in humans, PFOA does appear to
delay menarche in young girls [34].
An interesting observation that is currently unexplained was
that the plasma PFOA levels were much greater than expected with
the amount of PFOA added to the diet. For example, PFOA lev-
els measured in previous studies in mice that received 5 mg/kg
body weight by oral gavage [67,69] were comparable to values
obtained here when mice received lower PFOA doses (≈0.5 mg/kg
body weight). There are several possibilities for this result. First,
PFOA was fed with dietary fat and cholesterol. It is possible that
absorption rates of PFOA differ when fed in the presence of these
dietary factors. However, a recent study in hamsters fed fat and
a small amount of cholesterol and given daily doses of PFOA sug-
gests that this is not true as PFOA levels were similar in hamsters
fed fat or chow [15]. Second, it is possible that a greater proportion
of PFOA entered the circulation due to it being consumed through-
out the day, similar to what occurs in humans, and not in one bolus.
Third, though the PFOA does not appear to be carried in lipoproteins
[6], it is unknown if changes in metabolism with high fat diets are
such that clearance from the plasma could be delayed compared to
chow-fed rodents. Delayed clearance could result in accumulation
of PFOA over time. Though an analysis of NHANES data has found a
direct but non-signiﬁcant association between total fat intake and
serum PFOA [25], which was apparently not due to the presence of
PFOA in fatty foods [41], human dietary studies have not consid-
ered dietary fat a moderator of PFOA uptake by the gut. The very
high serum concentrations found in our animals do limit the inter-
pretation of ﬁndings and generalization to humans. Future studies
will need to repeat these studies with lower amounts of PFOA in
the same diet, individual PFOA plasma measurements, and with
different modes of administration, as well as address the potential
interaction of PFOA and dietary lipid.
Another unexplained ﬁnding was that female control mice had
plasma PFOA concentrations one order of magnitude higher than
the males (regardless of strain), assuming the pooled sample is rep-
resentative of an average of all 6 mice per group. While PFOA in the
control male mice was in the range of the median concentrations
in NHANES, the concentrations were much higher in the females.
As the control mice were not administered PFOA, they must have
been exposed to PFOA prior to reaching the university or be present
in our environment at low doses, i.e. in the chow. This is not unique
in that PFOA has been detected in control mice in previous stud-
ies as well [69,70]. It should be noted that PFOA levels also were
greater in the treated females versus males, though this was  likely
due to consumption of similar amounts of food while having less
body mass leading to increased PFOA consumption per kg body
weight. The causes of the sex differences are unknown, though in
humans males have higher serum concentrations of PFOA com-
pared to women  [25]. Future studies with more animals should
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. Conclusions
To summarize, we have shown that C57BL/6 and male BALB/c
ice exposed to PFOA have signiﬁcantly increased plasma choles-
erol levels when fed Westernized diets, consistent with human
bservational ﬁndings at the national [39,14] and community levels
16,19,60] and in adolescent [18,20] and occupational [44,56,57,9]
ohorts. As the majority of these human studies are cross-sectional
nd unable to assess causality, it has been difﬁcult to study causal-
ty because of the directionality difference between epidemiologic
uman and experimental rodent studies [46]. Our ﬁndings suggest
ouse PFOA responses are diet dependent, as suggested previously
ith other metabolic parameters [61], and this dependency may
xplain some of the differences in human and rodent response
bserved in the literature. Though additional studies with lower
evels of circulating PFOA are needed to model non-occupational
uman PFOA exposure and with mice genetically altered such
hat cholesterol can be transferred in plasma by CETP, the fat-fed
odents can be used to delineate the mechanism responsible for
ltered sterol metabolism in humans exposed to PFOA. Future stud-
es will need to take caution with the gender and strain used as these
ariables affect how mice respond to dietary factors with respect
o the development of hypercholesterolemia.
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